Cell Discovery · 2024 · 56 citations · 39 references
Life SciencesImmunologyPharmacologyCell TherapyClinical ImmunologyImmunotherapyAntiretroviral TherapyAntiviral ImmunityAntiviral TherapyCell-based ImmunotherapyCell-mediated ImmunityChimeric Antigen Receptor T-cell TherapyAntiviral T Cell ResponsesHiv Antiretroviral TherapyHiv Reservoir SuppressionImmune Reconstitution After Antiretroviral TherapyLatency Reversal TherapySuppressionT-cell Immune ResponsesTherapeutic Efficacy Assessment
Chimeric antigen receptor T (CAR-T) cells have been proposed for HIV-1 treatment but have not yet demonstrated desirable therapeutic efficacy. Here, we report newly developed anti-HIV-1 CAR-T cells armed with endogenic broadly neutralizing antibodies (bNAbs) and the follicle-homing receptor CXCR5, termed M10 cells. M10 cells were designed to exercise three-fold biological functions, including broad cytotoxic effects on HIV-infected cells, neutralization of cell-free viruses produced after latency reversal, and B-cell follicle homing. After demonstrating the three-fold biological activities, M10 cells were administered to treat 18 HIV-1 patients via a regimen of two allogenic M10 cell infusions with an interval of 30 days, with each M10 cell infusion followed by two chidamide stimulations for HIV-1 reservoir activation. Consequently, 74.3% of M10 cell infusions resulted in significant suppression of viral rebound, with viral loads declining by an average of 67.1%, and 10 patients showed persistently reduced cell-associated HIV-1 RNA levels (average decrease of 1.15 log10) over the 150-day observation period. M10 cells were also found to impose selective pressure on the latent viral reservoir. No significant treatment-related adverse effects were observed. Overall, our study supported the potential of M10 CAR-T cells as a novel, safe, and effective therapeutic option for the functional cure of HIV-1/AIDS.
39
MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0
Koichiro Tamura, Glen Stecher, Daniel S. Peterson et al. · Molecular Biology and Evolution · 2013 · 47.9K citations · Full text
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
Nancie M. Archin, Abigail Liberty, Angela D. M. Kashuba et al. · Nature · 2012 · 1.2K citations